Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 COPD exacerbations. 4: Prevention.

Literature DB >> 16648352

COPD exacerbations. 4: Prevention.

S Scott¹, P Walker, P M A Calverley.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16648352 PMCID： PMC2111200 DOI： 10.1136/thx.2005.041848

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

× No keyword cloud information.

90 in total

Review 1. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

Authors: M Johnson; S Rennard
Journal: Chest Date: 2001-07 Impact factor: 9.410

Review 2. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review.

Authors: P J Poole; P N Black
Journal: BMJ Date: 2001-05-26

3. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.

Authors: S I Rennard; W Anderson; R ZuWallack; J Broughton; W Bailey; M Friedman; M Wisniewski; K Rickard
Journal: Am J Respir Crit Care Med Date: 2001-04 Impact factor: 21.405

4. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Authors: Robert Wise; John Connett; Gail Weinmann; Paul Scanlon; Melissa Skeans
Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245

5. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.

Authors: D D Sin; J V Tu
Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405

6. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme.

Authors: T L Griffiths; C J Phillips; S Davies; M L Burr; I A Campbell
Journal: Thorax Date: 2001-10 Impact factor: 9.139

7. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.

Authors: M Miravitlles; C Murio; T Guerrero
Journal: Eur Respir J Date: 2001-05 Impact factor: 16.671

8. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.

Authors: R Dahl; L A Greefhorst; D Nowak; V Nonikov; A M Byrne; M H Thomson; D Till; G Della Cioppa
Journal: Am J Respir Crit Care Med Date: 2001-09-01 Impact factor: 21.405

9. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease.

Authors: J Hadcroft; P M Calverley
Journal: Thorax Date: 2001-09 Impact factor: 9.139

10. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.

Authors: C Stey; J Steurer; S Bachmann; T C Medici; M R Tramèr
Journal: Eur Respir J Date: 2000-08 Impact factor: 16.671

7 in total

1. Chronic obstructive pulmonary disease in China: the potential role of indacaterol.

Authors: Jinming Gao; Niyati Prasad
Journal: J Thorac Dis Date: 2013-08 Impact factor: 2.895

2. The burden of lung disease.

Authors: R Hubbard
Journal: Thorax Date: 2006-07 Impact factor: 9.139

Review 3. COPD: what is the unmet need?

Authors: P M A Calverley
Journal: Br J Pharmacol Date: 2008-09-15 Impact factor: 8.739

Review 4. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.

Authors: Ken M Kunisaki; Kathryn L Rice; Dennis E Niewoehner
Journal: Drugs Aging Date: 2007 Impact factor: 3.923